Globus Medical 10-Q: Q3 Sales Slip 0.7% to $763.7M, Buyback Raised $500M
GMED sits 29% above its 52-week low of $60.255 on elevated volume (2.8× avg).
Summary
Globus Medical's Q3 10-Q details a 0.7% sales decline to $763.7M on weak spinal cord stimulation and international sales, offset by operating income of $177.6M and a newly expanded $500M buyback authorization.
Key Events · Earnings and Guidance · GMED
-
Q3 Sales Decline 0.7%
Net sales were $763.7M versus $769.0M a year ago; U.S. rose 0.5% to $621.0M but international fell 5.7% to $142.7M, and spinal cord stimulation sales dropped $22.1M on lower U.S. trial volumes.
-
Operating Income Jumps to $177.6M
Q3 operating income rose from $137.4M to $177.6M as cost of sales fell 7.8% to $232.9M and the litigation provision dropped $24.6M; nine-month operating income was $510.4M versus $310.5M.
-
Buyback Raised by $500M
On November 2, 2026 the board authorized an additional $500.0M of Class A repurchases, leaving roughly $611.0M available; Q3 repurchases were 1.9M shares for $142.9M at an average $74.61.
-
Cash Flow and Balance Sheet
Nine-month operating cash flow was $677.3M versus $504.9M, with $441.3M of cash and equivalents plus $76.2M short-term and $353.7M long-term marketable securities at September 30, 2026.
Analysis · GMED · Industrial Applications And Services
The headline numbers were already out hours earlier, but the full 10-Q shows where the quarter actually went: U.S. sales grew just 0.5% to $621.0M while international fell 5.7% to $142.7M, and spinal cord stimulation revenue dropped $22.1M on weaker U.S. trial volumes. Profitability still improved sharply, with Q3 operating income of $177.6M versus $137.4M a year ago, helped by lower cost of sales and a $24.6M smaller litigation provision. Cash generation is strong at $677.3M for nine months, and the board added $500.0M to the buyback on November 2, 2026, leaving about $611.0M available — a real offset to the revenue guidance cut disclosed in the concurrent 8-K.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GMED was trading at $77.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $60.26 to $101.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.